It is one of the most common procurement questions that hospital pharmacists and oncology nurses encounter when a patient is first prescribed Zoladex: which one do we order — the 3.6mg or the 10.8mg? The question sounds simple. The answer requires understanding not just the difference in dose and interval but also which indications each formulation is approved for, why that distinction matters clinically, and what the practical implications are for hospital procurement and patient management. This article covers all of it without clinical dosing advice, and with full deference to the prescribing physician for all treatment decisions.
Topics
